Background Patients with chronic kidney disease have a high risk of adverse kidney and
cardiovascular outcomes. The effect of dapagliflozin in patients with chronic kidney disease, …

… dapagliflozin in chronic kidney disease (CKD) patients, with and without heart failure (HF). …
, end-stage kidney disease, or death from kidney cause was similar in these 2 patient groups: …

… Dapagliflozin is a selective inhibitor of sodium glucose co-… safety of dapagliflozin 10 mg vs
placebo in patients with type 2 … 59 mL/min/1.73 m 2 ; chronic kidney disease [CKD] stage 3A). …

… the effect on individual kidney diseases. Dapagliflozin reduced the risk of the primary
composite endpoint by 71% (HR, 0.29; 95% CI, 0.12 to 0.73) in patients with IgA nephropathy (n = …

… patients with or without type 2 diabetes and may explain the protective effects of dapagliflozin
in chronic kidney disease result… Our data indicate that the effects of dapagliflozin on all the …

… of dapagliflozin on the prespecified kidney and cardiovascular outcomes in patients with
chronic kidney disease … of cardiovascular disease, in the DAPA-CKD trial (Dapagliflozin and …

… In this prespecified subgroup analysis of the DAPA-CKD trial, we show beneficial effects
of dapagliflozin on kidney and cardiovascular end points in patients with stage 4 CKD at …

… in patients with chronic kidney disease. We aimed to investigate the effects of dapagliflozin
on kidney, … to underlying cause of chronic kidney disease, reported as diabetic nephropathy, …

… Dapagliflozin significantly slowed long-term eGFR decline in patients with chronic kidney
disease … The mean difference in eGFR slope between patients treated with dapagliflozin versus …

… kidney effects of the SGLT2 inhibitor dapagliflozin in patients with proteinuric kidney disease
… Notably, in our previous pilot study with dapagliflozin in patients with proteinuria caused by …